FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1658902377> ?p ?o ?g. }

• W1658902377 endingPage "479" @default.
• W1658902377 startingPage "466" @default.
• W1658902377 abstract "ABSTRACT Purpose The purpose of this study is to further evaluate the safety of the human papillomavirus (HPV)‐16/18‐AS04‐adjuvanted vaccine (HPV‐16/18‐vaccine Cervarix ®, GlaxoSmithKline, Belgium) through a pooled analysis of data from 42 completed/ongoing clinical studies. Methods Unsolicited adverse events (AEs) were reported for 30 days after each dose. Medically significant conditions, serious AEs (SAEs), potential immune‐mediated diseases (pIMDs) and pregnancy outcomes were captured until study completion. Events leading to subject withdrawal were reviewed. Relative risks compared incidences of spontaneous abortion and pIMDs in controlled studies. Results Thirty one thousand one hundred seventy‐three adolescent girls/women received HPV‐16/18‐vaccine alone (HPV group), 2166 received HPV‐16/18‐vaccine coadministered with another vaccine and 24 241 were controls. Mean follow‐up was 39 months (range 0–113.3). Incidences of unsolicited AEs reported within 30 days after any dose were similar between HPV and Control groups (30.8%/29.7%). During the entire study period, reports of medically significant conditions (25.0%/28.3%) and SAEs (7.9%/9.3%) were also similarly distributed between groups. Deaths were rare: HPV (alone/coadministered) n = 25, controls n = 20 ( n = 18 in blinded groups). pIMDs within 1 year were reported by 0.2% of HPV‐16/18 vaccinees and controls. For each pIMD event category, no increased relative risks were reported for HPV‐16/18 vaccinees versus controls. Coadministration did not change the overall safety profile. Pregnancy outcomes and withdrawal rates were similar between groups. Conclusions Analysis of safety data arising from 57 580 subjects and 96 704 HPV‐16/18‐vaccine doses shows that the incidences and distribution of AEs were similar among HPV‐16/18‐vaccine recipients and controls. No new safety signals were identified. The data confirm previous findings that HPV‐16/18‐vaccine has an acceptable benefit‐risk profile in adolescent girls and adult women. © 2014 GlaxoSmithKline. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd." @default.
• W1658902377 created "2016-06-24" @default.
• W1658902377 creator A5019152388 @default.
• W1658902377 creator A5024355009 @default.
• W1658902377 creator A5045860024 @default.
• W1658902377 creator A5051707431 @default.
• W1658902377 creator A5052308275 @default.
• W1658902377 creator A5080997025 @default.
• W1658902377 creator A5083823901 @default.
• W1658902377 date "2014-02-20" @default.
• W1658902377 modified "2023-10-16" @default.
• W1658902377 title "Pooled analysis of large and long‐term safety data from the human papillomavirus‐16/18‐AS04‐adjuvanted vaccine clinical trial programme" @default.
• W1658902377 cites W1561836836 @default.
• W1658902377 cites W1964375899 @default.
• W1658902377 cites W1965782309 @default.
• W1658902377 cites W1968111688 @default.
• W1658902377 cites W1979230907 @default.
• W1658902377 cites W1979240321 @default.
• W1658902377 cites W1996985859 @default.
• W1658902377 cites W2013513561 @default.
• W1658902377 cites W2017096286 @default.
• W1658902377 cites W2019479626 @default.
• W1658902377 cites W2030164196 @default.
• W1658902377 cites W2049058594 @default.
• W1658902377 cites W2049940896 @default.
• W1658902377 cites W2055201402 @default.
• W1658902377 cites W2057706962 @default.
• W1658902377 cites W2057825828 @default.
• W1658902377 cites W2070050362 @default.
• W1658902377 cites W2073221620 @default.
• W1658902377 cites W2077296152 @default.
• W1658902377 cites W2087404749 @default.
• W1658902377 cites W2087595040 @default.
• W1658902377 cites W2088740001 @default.
• W1658902377 cites W2098491904 @default.
• W1658902377 cites W2099289950 @default.
• W1658902377 cites W2102245223 @default.
• W1658902377 cites W2113802001 @default.
• W1658902377 cites W2114391710 @default.
• W1658902377 cites W2128393824 @default.
• W1658902377 cites W2135053575 @default.
• W1658902377 cites W2135671488 @default.
• W1658902377 cites W2136236728 @default.
• W1658902377 cites W2139736159 @default.
• W1658902377 cites W2150436558 @default.
• W1658902377 cites W2153385867 @default.
• W1658902377 cites W2162590249 @default.
• W1658902377 cites W2165308280 @default.
• W1658902377 cites W2167222579 @default.
• W1658902377 cites W2191914120 @default.
• W1658902377 cites W2319596822 @default.
• W1658902377 cites W4239392382 @default.
• W1658902377 doi "https://doi.org/10.1002/pds.3554" @default.
• W1658902377 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4230467" @default.
• W1658902377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24644063" @default.
• W1658902377 hasPublicationYear "2014" @default.
• W1658902377 type Work @default.
• W1658902377 sameAs 1658902377 @default.
• W1658902377 citedByCount "80" @default.
• W1658902377 countsByYear W16589023772014 @default.
• W1658902377 countsByYear W16589023772015 @default.
• W1658902377 countsByYear W16589023772016 @default.
• W1658902377 countsByYear W16589023772017 @default.
• W1658902377 countsByYear W16589023772018 @default.
• W1658902377 countsByYear W16589023772019 @default.
• W1658902377 countsByYear W16589023772020 @default.
• W1658902377 countsByYear W16589023772021 @default.
• W1658902377 countsByYear W16589023772022 @default.
• W1658902377 countsByYear W16589023772023 @default.
• W1658902377 crossrefType "journal-article" @default.
• W1658902377 hasAuthorship W1658902377A5019152388 @default.
• W1658902377 hasAuthorship W1658902377A5024355009 @default.
• W1658902377 hasAuthorship W1658902377A5045860024 @default.
• W1658902377 hasAuthorship W1658902377A5051707431 @default.
• W1658902377 hasAuthorship W1658902377A5052308275 @default.
• W1658902377 hasAuthorship W1658902377A5080997025 @default.
• W1658902377 hasAuthorship W1658902377A5083823901 @default.
• W1658902377 hasBestOaLocation W16589023771 @default.
• W1658902377 hasConcept C121608353 @default.
• W1658902377 hasConcept C126322002 @default.
• W1658902377 hasConcept C131872663 @default.
• W1658902377 hasConcept C168563851 @default.
• W1658902377 hasConcept C187212893 @default.
• W1658902377 hasConcept C197934379 @default.
• W1658902377 hasConcept C203014093 @default.
• W1658902377 hasConcept C22070199 @default.
• W1658902377 hasConcept C2777105317 @default.
• W1658902377 hasConcept C2777265743 @default.
• W1658902377 hasConcept C2778220009 @default.
• W1658902377 hasConcept C2779234561 @default.
• W1658902377 hasConcept C2909042557 @default.
• W1658902377 hasConcept C29456083 @default.
• W1658902377 hasConcept C2994532551 @default.
• W1658902377 hasConcept C535046627 @default.
• W1658902377 hasConcept C54355233 @default.
• W1658902377 hasConcept C71924100 @default.
• W1658902377 hasConcept C86803240 @default.
• W1658902377 hasConceptScore W1658902377C121608353 @default.

• next